Variations in genes such as patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), glucokinase regulator (GCKR), and hydroxysteroid 17-β dehydrogenase-13 (HSD17B13) have emerged as reproducibly and robustly predisposing individuals to the development of MASH [22,23]. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatohepatitis.